Breaking News Instant updates and real-time market news.

AAPL

Apple

$161.50

2.87 (1.81%)

, GS

Goldman Sachs

$227.42

6.36 (2.88%)

12:41
09/12/17
09/12
12:41
09/12/17
12:41

On The Fly: Top stock stories at midday

Stocks opened in positive territory and have remained there throughout the morning, moving in a very narrow range in the process. The tech heavy Nasdaq has been lagging the other averages as investors await the beginning of Apple's (AAPL) product reveal event at 1:00 pm ET. Apple events always have the potential to move the Dow members stock and those of its myriad suppliers and partners, and that effect may be amplified this time as the company takes the wraps of its tenth anniversary iPhone. COMPANY NEWS: Shares of several big banks rose following their presentations at the Barclays Global Financial Services Conference. Goldman Sachs (GS) shares rose nearly 3% after it said at the event that it sees $5B in revenue growth opportunities over the next three years, while shares of Wells Fargo (WFC) were almost 2% higher at midday after guiding for 2017 net interest income growth in the low to mid single digits. In addition, State Street (STT) shares saw a 1% bump after chief financial officer Eric Aboaf said at the conference that the bank is optimistic about regulatory change, though Aboaf added that he thinks it will "take time"... Meanwhile, Apple shares are in focus ahead of the company's keynote address at the tech giant's headquarters in Cupertino, California. The company is anticipated to unveil a series of new iPhones that will include a premium model, which some refer to as the iPhone X, expected to have a starting price that may top $1,000. In addition, Apple is expected to introduce a new way to unlock its smart phones, known as infrared face recognition, as well as Apple Watch upgrades. MAJOR MOVERS: Among the noteworthy gainers was Inovalon (INOV), which advanced 20% after the stock was upgraded to Equal Weight from Underweight at Morgan Stanley. Also higher was Comerica (CMA), which gained 4% after the stock was upgraded to Overweight from Neutral at Piper Jaffray. Among the notable losers was Health Insurance Innovations (HIIQ), which fell 16% after the company attempted to address "misleading" information regarding Richard Perason's short report released yesterday, saying the author "mischaracterized" certain disclosure questions and took certain comments "out of context." Also lower was Intercept Pharmaceuticals (ICPT), which fell 13% after the company sent a letter to health care providers highlighting the fact that liver injury, liver decompensation, liver failure, and death have been reported in primary biliary cholangitis patients with moderate or severe hepatic impairment when Ocaliva was dosed more frequently than recommended. INDEXES: Near midday, the Dow was up 65.63, or 0.3%, to 22,123.00, the Nasdaq was up 13.62, or 0.21%, to 6,445.89, and the S&P 500 was up 6.68, or 0.27%, to 2,494.79.

AAPL

Apple

$161.50

2.87 (1.81%)

GS

Goldman Sachs

$227.42

6.36 (2.88%)

WFC

Wells Fargo

$51.50

0.835 (1.65%)

STT

State Street

$95.29

0.96 (1.02%)

INOV

Inovalon

$14.65

0.35 (2.45%)

CMA

Comerica

$69.60

2.85 (4.27%)

HIIQ

Health Insurance Innovations

$23.35

-6.55 (-21.91%)

ICPT

Intercept

$113.48

-3.43 (-2.93%)

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 13

    Sep

  • 18

    Sep

  • 22

    Sep

  • 13

    Oct

  • 17

    Oct

  • 23

    Oct

  • 29

    Nov

  • 15

    Jan

AAPL Apple
$161.50

2.87 (1.81%)

09/12/17
BERN
09/12/17
NO CHANGE
BERN
Apple iPhone supply chain may be under pressure, says Bernstein
Ahead of today's Apple event, Bernstein analyst David Dai says he believes share prices of iPhone supply chain may be under pressure in the next 1-3 months and suggests investors to switch from iPhone supply chain companies to non-Apple suppliers to position themselves toward the iPhone launch. Additionally, the analyst says he does not expect major surprises from Apple's event.
09/12/17
JPMS
09/12/17
NO CHANGE
Target $315
JPMS
Overweight
JPMorgan still confident Apple will integrate Broadcom's wireless charging
Ahead of today's next generation iPhone announcement, JPMorgan analyst Harlan Sur says he remains confident that Apple (AAPL) will integrate Broadcom's (AGO) wireless charging chip into the next iPhone family in the second half of 2017. Broadcom commenced manufacturing production of the chip back in late June with its foundry partners, Sur tells investors in a research note. The analyst is also confident that Apple will also use Broadcom's next generation Wi-Fi/Bluetooth combo chip which enables simultaneous Wi-Fi data transmit/receive on both 2.4Ghz/5Ghz bands and the new Bluetooth 5.0 standard. He sees at least a $3-$4 step-up, or 40%-45% increase, in dollar content for Broadcom in the new iPhone relative to last year's models. Sur reiterates an Overweight rating on Broadcom with a $315 price target.
09/12/17
UBSW
09/12/17
NO CHANGE
Target $180
UBSW
Buy
Apple shares should outperform over next 6-12 months, says UBS
UBS analyst Steven Milunovich said Apple's stock performance from the last five product announcements has been pretty consistent, with the stock historically being down in the two weeks preceding the event, up or down 1%-2% the day of the event, up between the event and the launch, and up heading into earnings. He thinks there is somewhat greater near-term downside risk this time, but expects the stock to outperform over the next 6-12 months. Milunovich reiterated his Buy rating and $180 price target on Apple shares.
09/12/17
JPMS
09/12/17
NO CHANGE
JPMS
JPMorgan lays out iPhone content winners and losers into launch event
JPMorgan analyst Harlan Sur believes Apple's (AAPL) launch event today will be positive for Broadcom (AVGO) and Qorvo (QRVO) as well as Micron (MU) and Intel (INTC). The analyst sees content gains by Broadcom in wireless charging, touch controller, Wi-Fi/Bluetooth and GPS connectivity, and by Qorvo in low band power amplifier duplexers share and antenna tuning. Other companies with significant Apple exposure that would benefit from increased unit sales and/or modest content gains include Intel, Skyworks (SWKS), Knowles (KN), Micron, Cypress Semiconductor (CY), NXP Semiconductors (NXPI) and Texas Instruments (TXN), Sur tells investors in a research note. The analyst sees Analog Devices' (ADI) blended content at Apple declining as he believes the company will not be the touch controller for the OLED-version of the iPhone.
GS Goldman Sachs
$227.42

6.36 (2.88%)

07/24/17
07/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying the market seems to be pricing in an inflection in Goldman's trading revenue despite the recent weakness, suggesting a recovery is needed to justify 2018 consensus estimates. 2. Constellation Brands (STZ) downgraded to Neutral from Conviction Buy at Goldman Sachs. 3. Boston Beer (SAM) downgraded to Sell from Neutral at Goldman Sachs with analyst Judy Hong saying she sees further downside risk from weaker volumes and believes 2018 will be another year of volume decline and limited margin offset. 4. athenahealth (ATHN) downgraded to Underweight from Equal-Weight at First Analysis with analyst Frank Sparacino saying the valuation at current share levels is ahead of the underlying fundamentals in the short term. 5. PPG (PPG) was downgraded to Hold from Buy at SunTrust and to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
UBSW
07/24/17
DOWNGRADE
Target $230
UBSW
Neutral
Goldman Sachs downgraded to Neutral from Buy at UBS
UBS analyst Brennan Hawken downgraded Goldman Sachs (GS) to Neutral and cut his price target for the shares to $230 from $255. The bank closed Friday down $2.12 to $220.18. The market seems to be pricing in an inflection in Goldman's trading revenue despite the recent weakness, suggesting a recovery is needed to justify 2018 consensus estimates, Hawken tells investors in a research note. The analyst sees better opportunities for investors, such as Morgan Stanley (MS), as he has "limited confidence" in a revenue recovery at Goldman.
08/11/17
HSBC
08/11/17
DOWNGRADE
HSBC
Hold
Goldman Sachs downgraded to Hold from Buy at HSBC
08/09/17
WELS
08/09/17
INITIATION
Target $265
WELS
Outperform
Goldman Sachs resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of Goldman Sachs (GS) with an Outperform rating and $265 price target. The analyst prefers Goldman over Morgan Stanley (MS), saying the bank has about "twice as fast" organic revenue growth for more than 20 years, and "much faster" earnings growth over 15 years. Mayo named Citi (C) his top pick among the Large-Cap banks.
WFC Wells Fargo
$51.50

0.835 (1.65%)

07/31/17
BMOC
07/31/17
UPGRADE
BMOC
Market Perform
Wells Fargo upgraded to Market Perform from Underperform at BMO Capital
07/31/17
07/31/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Sector Perform from Underperform at RBC Capital with analyst Nik Modi saying he believes the FDA's tobacco announcement on Friday was "very much in line" with industry expectations despite the surprise to investors. 2. American Airlines (AAL) upgraded to Outperform from Market Perform at Cowen. 3. Baidu (BIDU) upgraded to Buy from Neutral at Nomura Instinet with analyst Jialong Shi-NIHK citing accelerating revenue momentum driven by news feed ads and an undervalued video business. 4. Wells Fargo (WFC) upgraded to Market Perform from Underperform at BMO Capital with analyst James Fotheringham citing valuation. The firm also ended its pair trade call of going long Citi (C) and short Wells Fargo. 5. GoPro (GPRO) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Yuuji Anderson saying valuation better reflects efforts to driver better product cycles through software improvements. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/17
BMOC
07/31/17
DOWNGRADE
BMOC
Market Perform
Citi downgraded on valuation, lack of catalysts at BMO Capital
As noted earlier, BMO Capital downgraded Citi (C) to Market Perform from Outperform. Analyst James Fotheringham downgraded the stock based on valuation and lack of catalysts. In conjunction with this note, he upgraded Wells Fargo (WFC) to Outperform from Market Perform and ended his pair trade call of going long Citi and short Wells Fargo. Target on Citi is $65.
07/31/17
BMOC
07/31/17
UPGRADE
BMOC
Market Perform
Wells Fargo upgraded on valuation at BMO Capital
As noted earlier, BMO Capital upgraded Wells Fargo (WFC) to Market Perform from Underperform. Analyst JamesFotheringham upgraded the stock based on valuation. In conjunction with the note, the firm downgraded Citi (C) to Market Perform from Outperform, and ended its pair trade call of going long Citi and short Wells Fargo. Target on Wells Fargo is $49.
STT State Street
$95.29

0.96 (1.02%)

06/28/17
GSCO
06/28/17
UPGRADE
Target $100
GSCO
Conviction Buy
State Street upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Alexander Blostein added State Street to the Conviction Buy List and increased its price target to $100 from $92 saying pre-tax margin targets look conservative, providing confidence in above consensus estimates. The analyst estimates fee growth grew 4%+ quarter-over-quarter in Q2 due to a favorable fee mix shift amid non-US equities outperformance and flows accelerated into the company's higher-fee ETFs.
08/09/17
WELS
08/09/17
INITIATION
Target $115
WELS
Outperform
State Street initiated with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo started State Street with an Outperform rating and $115 price target.
07/27/17
EVER
07/27/17
UPGRADE
Target $95
EVER
In Line
State Street upgraded to In Line from Underperform at Evercore ISI
Evercore ISI analyst Glenn Schorr upgraded State Street to In Line with a $95 price target following the strong Q2 report citing improved execution and expects share to perform inline with the group despite continued fee pressure and competitive threats.
07/27/17
07/27/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Boeing (BA) was upgraded to Outperform from Neutral at Credit Suisse, to Buy from Neutral at BofA/Merrill, to Neutral from Sell at Goldman Sachs, and to Sector Perform from Underperform at RBC Capital. 2. State Street (STT) upgraded to In Line from Underperform at Evercore ISI with analyst Glenn Schorr citing improved execution and expects share to perform inline with the group despite continued fee pressure and competitive threats. 3. Vermilion Energy (VET) upgraded to Outperform from Sector Perform at RBC Capital. 4. DDR Corp. (DDR) upgraded to Buy from Hold at Deutsche Bank with analyst Vin Chao saying new management's progress towards balance sheet and disposition plans has much improved FFO visibility. 5. Rockwell Automation (ROK) upgraded to Neutral from Underweight at JPMorgan with analyst C. Stephen Tusa saying the company reported another quarter of "strong organic growth and solid fundamentals." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
INOV Inovalon
$14.65

0.35 (2.45%)

09/12/17
09/12/17
UPGRADE
Target $14

Equal Weight
Inovalon upgraded to Equal Weight on better visibility at Morgan Stanley
As previously reported, Morgan Stanley analyst Ricky Goldwasser upgraded Inovalon to Equal Weight from Underweight, stating that the company's presentation at the firm's healthcare conference provided a line of sight to organic earnings acceleration in the second half of the year. The analyst, who notes that headwinds from the transition to per member per month pricing are now being lapped, raised his 2017 estimates for Inovalon and increased his price target on the stock to $14 from $9.
02/23/17
PIPR
02/23/17
NO CHANGE
Target $7
PIPR
Underweight
Piper views Inovalon outlook as 'overly optimistic'
Piper Jaffray analyst Sean Wieland lowered his price target for Inovalon shares to $7 from $8 saying the company's 2017 outlook is "overly optimistic." Inovalon provided little detail on how it will go from an 18% revenue decline in the second half of 2016 to down 11% in the first half of 2017 to up 11% in the second half of the year, Wieland tells investors in a research note. While management said the whistleblower lawsuit unsealed last week against United alleging systemic Medicare Advantage fraud is without merit, the analyst expects the suit to change the risk adjustment landscape and drive greater insourcing of the function, which he thinks will likely pressure renewal rates. Wieland keeps an Underweight rating on Inovalon.
09/12/17
09/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comerica (CMA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Brett Rabatin saying the bank's mid-quarter update is better than expected. 2. Alcoa (AA) upgraded to Buy from Hold at Deutsche Bank with analyst Jorge Beristain basing the upgrade on the firm's commodity team raising its 2018 aluminum price forecast by 12% to $2,072 per ton. 3. Kroger (KR) upgraded to Buy from Hold at Pivotal Research with analyst Ajay Jain saying continued weakness in investor sentiment following Kroger's latest results presents a near-term buying opportunity. 4. Comcast (CMCSA) upgraded to Buy from Neutral at MoffettNathanson with analyst Craig Moffett saying Comcast shares cheap following management comments on third quarter subscriber loses and the resulting stock selloff is overdone. 5. Inovalon (INOV) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Ricky Goldwasser saying that the company's presentation at the firm's healthcare conference provided a line of sight to organic earnings acceleration in the second half of the year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
MSCO
09/12/17
UPGRADE
MSCO
Equal Weight
Inovalon upgraded to Equal Weight from Underweight at Morgan Stanley
CMA Comerica
$69.60

2.85 (4.27%)

06/09/17
06/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Zynga (ZNGA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Brian Nowak saying the company's in-game innovation, starting with Poker, is resulting in higher engagement and monetization. 2. Citi (C) upgraded to Neutral from Sell at UBS with analyst Saul Martinez saying he sees an improved risk/reward at current share levels. Global growth "looks resilient," protectionist policies have not emerged, and the path forward for structural reforms in the U.S. "is not as clear." 3. Comerica (CMA) upgraded to Outperform from Market Perform at FBR Capital. 4. Camping World (CWH) upgraded to Buy from Neutral at Goldman Sachs with analyst David Tamberrino saying he expects growth to continue despite late-cycle concerns. 5. Humana (HUM) upgraded to Buy from Hold at Argus with analyst David Toung saying he is upbeat about its growth outlook following the termination of its merger deal with Aetna (AET). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
PIPR
09/12/17
UPGRADE
PIPR
Overweight
Comerica upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Brett Rabatin upgraded Comerica to Overweight and raised his price target for the shares to $80 from $76 saying the bank's mid-quarter update is better than expected. The analyst believes the recent pullback in shares creates an attractive entry point.
08/09/17
WELS
08/09/17
INITIATION
Target $73
WELS
Market Perform
Comerica resumed with a Market Perform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of Comerica with a Market Perform rating and $73 price target.
HIIQ Health Insurance Innovations
$23.35

-6.55 (-21.91%)

09/05/17
ADAM
09/05/17
NO CHANGE
Target $39
ADAM
Buy
Health Insurance Innovations weakness a buying opportunity, says Canaccord
Canaccord analyst Richard Close said the recent pullback in Health Insurance Innovations had provided a good entry point and he recommends buying the weakness. The analyst sees a less stabilized ACA market as a positive for the company, as higher premium rates and fewer options give people a reason to look at lower-cost alternatives from Health Insurance Innovations. Close reiterated his Buy rating and $39 price target on the shares.
09/12/17
ADAM
09/12/17
NO CHANGE
ADAM
Buy
Health Insurance Innovations regulatory items will get resolved, says Canaccord
Canaccord analyst Richard Close believes Health Insurance Innovations' outstanding regulatory issues will be resolved without a meaningful impact on the business, but said it could take time and remain an overhang until this is settled. Close maintains a Buy rating and said the next likely catalysts for shares would be a resolution to the Florida third-party administrator license application situation.
09/01/17
ADAM
09/01/17
NO CHANGE
Target $39
ADAM
Buy
Health Insurance Innovations pullback a buying opportunity, says Canaccord
Canaccord analyst Richard Close attributes the sharp pullback in Health Insurance Innovations yesterday that has continued into this morning to a New York Times article quoting a White House official as saying the administration wants to stabilize the ACA insurance market. This was followed by several media reports that the government would be cutting funding for ACA advertising by 90% and funding for the navigator program by 40%, Close added. While less advertising and funding to promote the ACA could mean fewer people will seek lower-cost alternatives, a negative for Health Insurance Innovations, he thinks this news could actually be positive for the company since less advertising also implies a potentially lower cost per lead/conversion and he still expects solid demand for its offerings. Close, who recommends buying the stock on the pullback, keeps a Buy rating and $39 price target on Health Insurance Innovations shares.
09/11/17
CANT
09/11/17
NO CHANGE
Target $38
CANT
Overweight
Health Insurance Innovations weakness 'mostly unfounded,' says Cantor
Cantor Fitzgerald analyst Steven Halper said he views the weakness in Health Insurance Innovations following a short report issued on the stock as "mostly unfounded." One of the central focuses of the report is the ongoing 42-state investigation into operating practices that was previously disclosed and he sees the claim of a potential $100M in penalties as unfounded. He has spoken to the company and noted that management intends to host an investor/analyst call later today, he tells investors. Halper has an Overweight rating and $38 price target on Health Insurance Innovations shares, which are off their lows but remain down over 25% in afternoon trading.
ICPT Intercept
$113.48

-3.43 (-2.93%)

09/12/17
CANT
09/12/17
NO CHANGE
Target $69
CANT
Underweight
Cantor reiterates $69 target on Intercept after Ocaliva warning letter
Cantor Fitzgerald analyst Elemer Piros reiterates an Underweight rating on Intercept Pharmaceuticals after the company sent a letter to healthcare providers warning that serious liver injuries, including death, have been reported in liver-impaired primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. The news raises caution on the PBC franchise's future growth potential in more severe patients, and signals a "potential hurdle" for further penetration, Piros tells investors in a research note. Intercept in early trading is down 19% to $92.08.
09/12/17
SBSH
09/12/17
NO CHANGE
Target $240
SBSH
Buy
Intercept patient safety letter a 'meaningful negative,' says Citi
Citi analyst Joel Beatty calls Intercept Pharmaceuticals' patient safety letter a "meaningful negative" for Intercept Pharmaceuticals. The letter could "dampen physician enthusiasm" to prescribe Ocaliva in primary biliary cholangitis, especially if other competing agents are approved, Beatty tells investors in a research note. He also believes the news is likely to raise investor concerns about the safety of obeticholic acid in nonalcoholic steatohepatitis. The analyst notes that Intercept, when asked, see no impact on the Phase 3 Regenerate trial of OCA in NASH. Intercept in early trading is down 20%, or $22.34, to $91.14. Beatty keeps a Buy rating on the shares with a $240 price target. He notes his price target is largely based on NASH.
09/12/17
JEFF
09/12/17
NO CHANGE
JEFF
Intercept selloff an 'overreaction,' says Jefferies
Jefferies analyst Michael Yee said the sell off in Intercept shares is an "overreaction" to the "Dear Healthcare Provider Letter" and said the risk/benefit of OCA remains favorable. The analyst said there is no change to his Buy thesis and $275 price target and would be buyers of the stock and expects shares to recover as the Phase III trial in cirrhotic patients is initiated by year-end and as we approach Phase III NASH results in early 2019.
09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.

TODAY'S FREE FLY STORIES

16:40
09/22/17
09/22
16:40
09/22/17
16:40
General news
Moody's downgrades UK's rating to Aa2, changes outlook to stable »

Moody's Investors…

A

Agilent

$65.78

-0.14 (-0.21%)

, MRK

Merck

$65.13

-0.47 (-0.72%)

16:36
09/22/17
09/22
16:36
09/22/17
16:36
Hot Stocks
Agilent receives expanded FDA approval for the use of Dako PD-L1 IHC 22C3 »

Agilent Technologies…

A

Agilent

$65.78

-0.14 (-0.21%)

MRK

Merck

$65.13

-0.47 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

TYHT

Shineco

$3.23

-0.45 (-12.23%)

16:35
09/22/17
09/22
16:35
09/22/17
16:35
Hot Stocks
Shineco enters into strategic cooperation to establish Apocynum Industrial Park »

Shineco announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:34
09/22/17
09/22
16:34
09/22/17
16:34
Hot Stocks
Appliance Recycling gets written notice of default »

On September 20,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNVA

Rennova Health

$0.22

0.0086 (4.07%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Rennova Health announces 1 for 15 reverse stock split »

Rennova Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$1.16

0.03 (2.65%)

16:31
09/22/17
09/22
16:31
09/22/17
16:31
Hot Stocks
Breaking Hot Stocks news story on Appliance Recycling »

Appliance Recycling gets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/22/17
09/22
16:30
09/22/17
16:30
Options
Preliminary option volume of 13.9M today »

Preliminary option volume…

EKSO

Ekso Bionics

$1.28

0.14 (12.28%)

16:23
09/22/17
09/22
16:23
09/22/17
16:23
Hot Stocks
Ekso Bionics awarded government contract »

The Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

, AET

Aetna

$153.57

0.18 (0.12%)

16:22
09/22/17
09/22
16:22
09/22/17
16:22
General news
On The Fly: Top stock stories for Friday »

The major averages…

UNH

UnitedHealth

$193.03

-2.18 (-1.12%)

AET

Aetna

$153.57

0.18 (0.12%)

ANTM

Anthem

$182.86

-0.64 (-0.35%)

CI

Cigna

$182.74

0.61 (0.33%)

AAPL

Apple

$151.89

-1.5 (-0.98%)

FSLR

First Solar

$51.41

2.65 (5.43%)

FINL

Finish Line

$9.73

0.51 (5.53%)

ASND

Ascendis Pharma

$34.24

6.5 (23.43%)

VSAR

Versartis

$2.68

-18.925 (-87.62%)

ICPT

Intercept

$61.59

-12.11 (-16.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Oct

DLR

Digital Realty

$114.51

-1.72 (-1.48%)

16:19
09/22/17
09/22
16:19
09/22/17
16:19
Syndicate
Breaking Syndicate news story on Digital Realty »

Digital Realty files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:17
09/22/17
09/22
16:17
09/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$69.09

0.28 (0.41%)

16:16
09/22/17
09/22
16:16
09/22/17
16:16
Hot Stocks
TSYS announces resignation of COO Pamela Joseph »

TSYS announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
09/22/17
09/22
16:16
09/22/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$170.54

-0.57 (-0.33%)

16:15
09/22/17
09/22
16:15
09/22/17
16:15
Hot Stocks
Facebook's Zuckerberg plans to sell up to 75M shares to fund charity initiatives »

On September 22 Mr.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

IDA

IDACORP

$87.79

-0.73 (-0.82%)

16:13
09/22/17
09/22
16:13
09/22/17
16:13
Hot Stocks
IDACORP raises quarterly dividend 7.3% to 59c per share »

The dividend declaration,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRX

Valeritas

$3.06

-0.23 (-6.99%)

16:13
09/22/17
09/22
16:13
09/22/17
16:13
Syndicate
Valeritas announces common stock purchase agreement by Aspire Capital »

Valeritas Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$170.54

-0.57 (-0.33%)

16:12
09/22/17
09/22
16:12
09/22/17
16:12
Hot Stocks
Facebook dumps plan for new class of shares »

On September 21 the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

DCIX

Diana Containerships

$0.42

-0.0373 (-8.16%)

16:11
09/22/17
09/22
16:11
09/22/17
16:11
Hot Stocks
Diana Containerships announces one-for-three reverse stock split »

Diana Containerships…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEP

Spectra Energy Partners

$43.89

0.34 (0.78%)

16:10
09/22/17
09/22
16:10
09/22/17
16:10
Syndicate
Breaking Syndicate news story on Spectra Energy Partners »

Spectra Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEV

Sevcon

$22.04

0.04 (0.18%)

, BWA

BorgWarner

$50.00

0.41 (0.83%)

16:10
09/22/17
09/22
16:10
09/22/17
16:10
Hot Stocks
Sevcon stockholders approve acquisition by BorgWarner »

Sevcon (SEV) announced…

SEV

Sevcon

$22.04

0.04 (0.18%)

BWA

BorgWarner

$50.00

0.41 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Oct

ATOS

Atossa Genetics

$0.49

-0.0296 (-5.71%)

16:07
09/22/17
09/22
16:07
09/22/17
16:07
Syndicate
Breaking Syndicate news story on Atossa Genetics  »

Atossa Genetics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$142.68

-0.27 (-0.19%)

16:06
09/22/17
09/22
16:06
09/22/17
16:06
Hot Stocks
Chubb CEO issues statement on EU-U.S. covered agreement »

Evan Greenberg, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 31

    Jan

AAPL

Apple

$153.39

-2.68 (-1.72%)

15:40
09/22/17
09/22
15:40
09/22/17
15:40
Options
Active trading in Apple as iPhone 8 makes a debut »

Active trading in Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

MRK

Merck

15:39
09/22/17
09/22
15:39
09/22/17
15:39
Hot Stocks
Merck gets FDA approval for Keytruda »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 08

    Nov

  • 30

    Nov

TAL

TAL Education

$33.09

-0.45 (-1.34%)

15:35
09/22/17
09/22
15:35
09/22/17
15:35
Options
Tal Education Group put volume heavy and directionally bearish »

Bearish flow noted in Tal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.